文献速递外周动脉疾病

自体静脉旁路术在慢性肢体威胁性缺血股腘动脉病变中优于腔内治疗

In Situ Vein Bypass Is Superior to Endovascular Treatment of Femoropopliteal Lesions in Chronic Limb-Threatening Ischemia.
PubMed 文献 · Ann Vasc Surg · 2020-03-29

该单中心非随机研究纳入2011至2015年679例因慢性肢体威胁性缺血(CLTI)首次接受股腘动脉干预的患者,比较旁路术与腔内治疗。3年无截肢生存率自体静脉旁路为41.8%,显著优于PTA/S的29.7%和人工血管旁路的31.7%;腔内治疗组主要截肢或死亡风险增加56%。

要点

  • 自体静脉旁路术3年无截肢生存率优于PTA/S和人工血管旁路。
  • 腔内治疗组主要截肢或死亡风险较静脉旁路增加56%。
  • 尽管外科并发症更常见,静脉旁路在TASC B-C和D病变中均合理。

核心结论

  • 在CLTI股腘动脉病变中,自体静脉旁路术在无截肢生存和总死亡率方面优于PTA/S和人工血管旁路。

研究设计与样本

  • 单中心非随机研究,基于丹麦血管登记前瞻性数据,纳入2011至2015年679例因CLTI首次接受股腘动脉干预的患者。

主要发现

  • 3年无截肢生存率:静脉旁路41.8%(95%CI 35-48.4),PTA/S 29.7%(95%CI 22.7-37),人工血管旁路31.7%(95%CI 19-45.1)。
  • 调整合并症和TASC分类后,腔内治疗组主要截肢或死亡风险较静脉旁路增加(HR 1.56,95%CI 1.21-2.05)。
  • 旁路术组术后并发症、住院时间和再干预更频繁。

临床怎么用

  • 对于CLTI股腘动脉病变,自体静脉旁路术可作为优先考虑的血运重建方式。
  • 尽管外科并发症较多,静脉旁路在短病变(TASC B-C)和长病变(TASC D)中均合理。

局限性

  • 非随机研究设计可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objective of the study was to compare bypass surgery and endovascular revascularization of the femoropopliteal segment in patients with peripheral arterial disease and critical limb-threatening ischemia (CLTI). METHODS: This is a single-center study including patients undergoing first-time lower extremity intervention with peripheral bypass surgery or percutaneous transluminal angioplasty with or without stenting (PTA/S) of the femoropopliteal segment because of CLTI from 2011 to 2015. Based on prospective entered data from the Danish Vascular Registry, the primary end points were amputation-free survival, overall mortality, and reinterventions. RESULTS: A total of 679 patients with CLTI were included of which 35% (n = 239) were treated with PTA/S, 54% (n = 363) with vein bypass, and 11% (n = 77) with synthetic bypass. After 3 years, amputation-free survival was significantly better with a vein bypass (41.8% [95% CI: 35-48.4]) than both PTA/S (29.7% (95% CI: 22.7-37)) and synthetic bypass (31.7% [95% CI: 19-45.1]). Overall, the endovascular-treated patients faced more than 50% increased risk of major amputation or death than that of a vein bypass, after adjusting for comorbidity and Trans-Atlantic Inter-Society Consensus (TASC) classification (HR: 1.56 [95% CI: 1.21-2.05]). As expected, postoperative complications, length of hospital stay, and reinterventions were more frequent in the bypass groups. CONCLUSIONS: In this nonrandomized study, autologous vein bypass was superior to both PTA/S and synthetic bypass in regard to amputation-free survival and overall mortality. Despite the increased frequency of surgical complications, a vein bypass appears justified in both shorter (TASC B-C) and longer (TASC D) femoropopliteal lesions.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lawaetz M, Fisker L, Lönn L, et al. In Situ Vein Bypass Is Superior to Endovascular Treatment of Femoropopliteal Lesions in Chronic Limb-Threatening Ischemia. Ann Vasc Surg. 2020. PMID: 32234573. doi:10.1016/j.avsg.2020.03.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。